Send2Press Newswire
Tue, 16 Mar 2010 17:21:04 GMT
Epeius Biotechnologies Receives Notice of Patent Allowance for Tumor-Targeted Cancer Vaccines
Precision-targeted Reximmune-C® recruits cancer patient's inner SWAT team.
SAN MARINO, Calif., March 16 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for a crucial patent covering its leading tumor-targeted vaccine technology for cancer immunotherapy. The issuance of this valuable patent protection for tumor targeted immunotherapy follows on the heels of two international patents covering targeted gene medicine in the U.S. and Europe, respectively, and places Epeius Biotech at the forefront of these emerging fields of clinical medicine with best-of-breed solutions and incontrovertible proofs-of-principle in the clinic.
The advent of pathotropic (disease-seeking) targeting technology first enabled the development of tumor-targeted Rexin-G, which seeks-out, accumulates-in, and selectively delivers a lethal designer gene to tumors that have spread throughout the body (metastatic cancer), halting the progression of disease while improving both survival and quality-of-life. Approved for all solid tumors in the Philippines, Rexin-G has received Orphan Drug and Fast Track status from the U.S. FDA, and is currently moving on to Phase III trials for first-line and second-line indications.
Once the control of tumor growth has been achieved with Rexin-G®, the need to extend the treatment intervals and/or clinical remissions led to the development of Reximmune-C, a second tumor-targeted genetic medicine which delivers a pulse of immune-stimulating cytokine directly to the sites of residual or recurrent disease, thereby recruiting the patient's own immune system into the lesions of the residual cancer to invoke a more lasting anti-tumor immune response.
Much like a SWAT (special weapons and tactics) Team that calls an elite police force to the scene of a crime, Reximmune-C acts at the local level, recruiting the body's own professional immune cells, antigen-presenting cells, helper cells, and killer T-cells directly to the locus of the residual cancer, where tumor debris as antigens are abundant.
This provides the patient with an opportunity to mount a beneficial immune response that would further improve clinical outcome. Unlike, previous approaches to personalized cancer vaccination, a simple intravenous infusion of tumor-targeted Reximmune-C marshals the cadre of complex immunological responses of this intrinsic SWAT Team to the place where it is needed most. By reaching beyond the boundaries of medicine to the very crux of metastatic disease, Epeius delivers another vital innovation.
About Epeius Biotechnologies:
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems.
To learn more about our pipeline of proprietary biotechnologies, please visit us at www.epeiusbiotech.com.
NEWS SOURCE: Epeius Biotechnologies Corporation
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2010 Neotrope® News Network - all rights reserved.
TAGS: Epeius Biotechnologies Corporation, Drugs and Pharmaceuticals, Send2Press.
Tue, 16 Mar 2010 06:58:47 GMT
Patented CAVTEC Technology Quantifies Competitive Advantage and Value
SYRACUSE, N.Y., Nov. 5 (SEND2PRESS NEWSWIRE) -- CAVTEC (www.cavtectools.com) announces the formal launch of CAV, Competitive Advantage Valuation software for maximizing returns on intellectual property (IP). Field tested in over 100 projects since 1997, CAV has helped universities, businesses, and entrepreneurs develop effective IP strategies and negotiate successful agreements. As a result, in 2009 Technology Transfer Tactics (TTT) chose the CAV solution for its specialized valuation catalog (www.technologytransfertactics.com) and showcased CAV at the recent Licensing Executives Society (LES) annual meeting. TTT is a highly respected publication of best practices for research, commercialization and licensing professionals.
Ted Hagelin, CAVTEC CEO, notes: "We have seen tremendous growth in the value of IP. Today, about 83 percent of S&P 500 companies' market value is attributable to intangible property. As market value grew, so did the volume of IP exchanges and the importance of accurately and objectively valuing these assets in the absence of public trading markets and standardized exchange terms. Until now IP valuation methods have been either inexpensive but yielding very coarse results, or simply out of reach financially for most users. CAV was developed to strike a unique balance between cost and precision."
David Schwartz, TTT CEO and Publisher adds, "Technology Transfer Tactics is proud to partner with CAVTEC, because CAV fills a real need for our subscribers - a low-cost, comprehensive valuation tool that calculates an equal rate of return for licensors and licensees."
Mary Maida PhD, CEO of Medingen (www.medingen.com), a CAV customer, concurs, stating: "Our clients are in every stage of technology development, from feasibility through launch. We find CAV to be extremely useful and flexible."
About CAV:
CAV is a repeatable, comprehensive approach to IP valuation. It features a step-by-step method for quantifying factors that determine a technology's competitive advantage in a given market.
Packaged as PC-based software, key CAV applications include:
• valuing early-state technologies
• negotiating patent licenses
• determining venture investments
• predicting IP success in the marketplace
• performing due diligence
• calculating infringement damages.
CAV, patented by CAVTEC founder Ted Hagelin, is based on his extensive expertise. Hagelin is nationally recognized for IP valuation through his work as the Director of Syracuse University's Technology Commercialization Research Center and his research on intellectual property strategy and patent valuation. He teaches intellectual property and technology commercialization law at Syracuse University College of Law.
More information: www.cavtectools.com.
NEWS SOURCE: CAVTEC
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2009 Neotrope® News Network - all rights reserved.
TAGS: CAVTEC, Software, Send2Press.
Thu, 05 Nov 2009 18:52:31 GMT
Authernative Granted U.S. Patent on Key Generation Method for Encryption and Authentication System
REDWOOD CITY, Calif., Oct. 26 (SEND2PRESS NEWSWIRE) -- Authernative, Inc., the leading developer of innovative user authentication and identity management technologies, announced today that the United States Patent and Trademark Office has granted the company its patent for encryption key generation method. The newly issued U.S. Patent No. 7,577,987 titled "Key generation method for communication session encryption and authentication system" describes a new encryption key management system integrated with a two-factor authentication protocol.
This system provides for mutual authentication of the connected parties in a client-server architecture which results in a secure distribution of secret session-only random symmetric encryption keys that are generated at the server and distributed to clients.
The wide proliferation of B2B and B2C e-commerce networks enabling connections from user's mobile devices, laptop/desktop computers, ATMs, POS terminals, set-top boxes, VOIP phones, GPS and other data processing devices necessitates enhancement of the security infrastructure at the consumer level, especially in the area of user authentication and data-in-transit security. Usage of Public Key Infrastructure (PKI) has certain limitations at the mass user level due to technology deployment complexities, cost, and administration of the consumers' keys / certificates. Authernative-patented MEDIA™ protocol overcomes these PKI issues by using two-factor authentication credentials adopted in e-commerce with the benefit of providing seamless mutual authentication and a secure session-only random symmetric encryption key distribution enabling further secure data exchange.
"Authernative's encryption key management system enables an easy to administer high security solution," said Dr. Len Mizrah, President and CEO of Authernative. "The advantage of the MEDIA™ protocol is a capability to mutually authenticate with the server either a client platform or a human user at the client platform, depending on credentials utilized. In both cases, it protects from pharming or phishing attacks respectively."
The security of the key exchange in the MEDIA™ protocol is based on innovative algorithms enabling the following three Authernative-patented technologies: (1) a key generation architecture utilizing the Time Interplay Limited SRK (Session Random Key) Algorithm (TILSA™) - U.S. Patent No. 7,577,987, (2) a key exchange protocol utilizing the TILSA™ algorithm and communication parties' authentication credentials with Key Encryption/Decryption Iterative Algorithm (KEDIA™) - U.S. Patent No. 7,506,161, and (3) a Key Conversion Array (KCA™) technology providing for high security message exchange over non-trusted communication media by utilizing either of patented algorithms: Bit-Veil-Unveil (BitVU™), Byte-Veil-Unveil (ByteVU™), and Bit-Byte-Veil-Unveil (BBVU™) - U.S. Patent No. 7,299,356.
These patented technologies embedded into Authernative AuthGuard® user authentication product enable strong user authentication and client-server mutual authentication during the authentication stage of the communication session and secure exchanges of encryption keys to allow secure content delivery. The CrosSecure® Authernative® Cryptographic Module integrated into AuthGuard® has received FIPS 140-2 certification from the National Institute of Standards and Technology (USA).
AuthGuard® offers a suite of one-factor, layered, and multi-factor authentication to meet a variety of security and usability requirements. AuthGuard® user authentication is electronically mass deployable, has scalable security, high usability, low total cost of ownership, and efficient integration/customization options with legacy environments. The product provides fully automated operation modes for secure login, set-up, and reset of all AuthGuard® authentication methods including enhanced password, pattern-based one-time password, one-time challenge one-time response, out-of-band, one-time pin, and secure in-band authentication.
The newly granted patent solidifies the company's ability to provide innovative, secure and cost-effective user authentication solutions. With identity theft, cyber crime, and data breaches escalating to an all time high, enterprises, government agencies, online service providers, and consumers can benefit from the AuthGuard® authentication product to secure access to networks, extranets, portals, applications, data and devices.
About Authernative, Inc.:
Authernative is a leading provider of innovative software security solutions offering identity and access management capabilities including authentication, authorization, administration, and auditing. The company's products are used to prevent unauthorized online access to confidential data, protected resources, and financial transactions. They allow organizations to lower the cost of providing, deploying and managing user authentication for enabling e-commerce, e-government, and regulatory compliance.
More information: www.authernative.com.
NEWS SOURCE: Authernative, Inc.
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2009 Neotrope® News Network - all rights reserved.
TAGS: Authernative, Inc., Safety and Security Solutions, Send2Press.
Mon, 26 Oct 2009 12:30:28 GMT
Authernative Granted U.S. Patent for User Authentication System Operation Modes
REDWOOD CITY, Calif., Oct. 14 (SEND2PRESS NEWSWIRE) -- Authernative, Inc., the developer of innovative user authentication and identity management technologies, announced today that the United States Patent and Trademark Office has granted the company a patent for operation modes in a user authentication system. The newly issued U.S. Patent No. 7,577,987 titled, "Operation modes for user authentication system based on random partial pattern recognition" ("the Patent") describes a system of operation modes for self-service account administration of a "what user knows" based authentication system using random partial pattern recognition.
The Patent builds on Authernative's portfolio of user authentication patents by covering the operation modes for secure self-service set-up and self-reset of user accounts and authentication credentials. The patented system enables users to securely set-up and reset accounts and authentication credentials including usernames, e-mail addresses, personal profiles, security questions, temporary credentials, password credentials, and other authentication credentials used in a single- or multi-factor authentication based on random partial pattern recognition.
The security tiers and features offered by the newly patented system enhance the well known benefits of online self-service user authentication systems such as reduced support costs, anytime/anywhere access, and increased productivity. The result is an unparalleled secure self-service account administration that is immune from the security challenges and attacks plaguing user account login, set-up and reset. For example, security questions are commonly used for resetting passwords, but they alone do not provide sufficient security because they can be compromised or guessed by identity thieves. By contrast, Authernative's system protects against such back-door attacks by providing multi-tier account reset security, where at least two tiers must be successfully traversed before a user can reset the account.
The account login and reset security is further enhanced by random partial pattern recognition authentication, where the authentication server never challenges the user to provide the full secret pattern (authentication code such as a password, PIN, or graphical pattern), but instead requests a session-specific random subset of the secret pattern ("One Time Pattern"™ (OTP)). This significantly reduces the credential's entropy leakage and renders one-time authentication responses difficult to compromise, protecting users' credentials against phishing, key logging, brute force, Trojan horse and other spyware attacks. Moreover, the method's virtual reference grid and the scalable combinatorial capacity of the secret pattern provide high security against guessing attacks, while delivering a simple and more engaging user experience.
Authernative's patented system also provides multi-tier account set-up security options including temporary credentials, out-of-band delivery, and account release options. Additionally, the system logs all account administration and authentication events enabling automatic or human monitoring to detect unusual account administration activity, conduct forensic research, and meet regulatory compliance. This patent adds to the protected intellectual property and technology foundation for the company's AuthGuard® user authentication product.
AuthGuard® offers a suite of one-factor, layered, and multi-factor authentication to meet a variety of security and usability requirements. AuthGuard® user authentication is electronically mass deployable, has scalable security, high usability, low total cost of ownership, and efficient integration/customization options with legacy environments.
The product provides fully automated operation modes for secure login, set-up, and reset of all AuthGuard® authentication methods including enhanced password, graphical password, one-time challenge one-time response, out-of-band, one-time pin, and secure in-band authentication. The AuthGuard® crypto security of data-in-transit and data-at-rest is assured by the CrosSecure® Authernative® Cryptographic Module that has been FIPS 140-2 certified by the National Institute of Standards and Technology (USA).
Authernative's granted patent solidifies the company's ability to provide innovative, secure and cost-effective user authentication solutions. With identity theft, cyber crime, and data breaches escalating to an all time high, enterprises, government agencies, online service providers, and consumers can benefit from the AuthGuard® authentication product to secure access to networks, extranets, portals, applications, data and devices.
About Authernative, Inc.:
Authernative is a leading provider of innovative software security solutions offering identity and access management capabilities including authentication, authorization, administration, and auditing. The company's products are used to prevent unauthorized online access to confidential data, protected resources, and financial transactions. They allow organizations to lower the cost of providing, deploying and managing user authentication for enabling e-commerce, e-government, and regulatory compliance.
More information: www.authernative.com.
NEWS SOURCE: Authernative, Inc.
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2009 Neotrope® News Network - all rights reserved.
TAGS: Authernative, Inc., Patent and Trademark, Send2Press.
Wed, 14 Oct 2009 13:53:09 GMT
Patent Awarded for Waffletechnology Cleaning Cards to KICTeam
Waffletechnology cleaning cards are used in all industries.
AUBURN, Maine, July 8 (SEND2PRESS NEWSWIRE) -- A patent has been issued for a unique feature of KICTeam's Waffletechnology® cleaning cards, adding a level of protection to a growing cleaning card market. "We have been pursuing this patent since the early stages of Waffletechnology development and are pleased to have received the first of what we anticipate will be multiple patents," said Peter Klein, President/CEO at KICTeam, Inc.
 He added, "The Waffletechnology products are a huge success and have attracted a large number of Blue Chip OEMs - Original Equipment Manufacturers - who were seeking a cleaning tool for their equipment. When your largest end-user customer, New York City Transit, recognizes the effectiveness of Waffletechnology and is willing to upgrade all of their cleaning cards from flat to Waffletechnology with a cost increase, it is a testament to the effectiveness and legitimacy of the product. We decided early on to file a series of patent applications to aggressively protect our intellectual property."
"Our products have evolved with the equipment they maintain," said Debra Ross, Product Manager at KICTeam. "We invented our Waffletechnology cleaning cards to answer new problems arising in the transaction industry that our historical flat products could not solve. Since the first Waffletechnology product was released in 2004, we have launched 67 new products. The majority of these have developed from OEM requests to create a cleaning tool that will maintain the operation of their equipment. We have made products for JCM in the bill acceptor/validator industry, TransAct Technologies and Datamax-O'Neil in the Thermal Printer Industry, VidTroniX for its airline bag tag and boarding pass printers, and Panini, Epson and Canon for their check scanners used in the banking industry. We take pride in our OEM partnerships and the successful products that develop from them."
Waffletechnology® products have the ability to clean today's transaction equipment, which is susceptible to dust and pollution entering in and covering sensitive read heads and optical sensors. Until recently, most equipment needed to be opened by a technician to be properly cleaned, this is both costly and time consuming. Waffletechnology products provide a solution to this problem with their unique design, which allows them to clean areas without opening the equipment. Now, most equipment can be regularly cleaned and maintained by anybody who uses that equipment. For more information, visit: www.waffletechnology.com.
About KICTeam
KICTeam is the world leader in the development and manufacture of cleaning cards, including Waffletechnology® based patented products. Company growth in the last 20 years has been driven by the close cooperation with OEMs in the development of proprietary cleaning solutions. Company headquarters are in Auburn, Maine, with a worldwide presence through strategic partners.
For more information, please visit www.kicteam.com or www.cleaningcards.com.
All trademarks and service marks are the property of the respective parties.
NEWS SOURCE: KICTeam, Inc.
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2009 Neotrope® News Network - all rights reserved.
TAGS: KICTeam, Inc., Patent and Trademark, Send2Press.
Wed, 08 Jul 2009 16:48:48 GMT
Authernative Granted US Patent on Communication Session Encryption and Authentication System
REDWOOD CITY, Calif., April 14 (SEND2PRESS NEWSWIRE) -- Authernative, Inc., the leading developer of innovative user authentication and identity management technologies, announced today that the United States Patent & Trademark Office has granted the company its patent for a communication session encryption and authentication system.
 The newly issued US Patent No. 7,506,161 titled "Communication session encryption and authentication system" describes a new encryption key management system integrated with a two-factor authentication protocol. This system provides for mutual authentication of the connected parties in a client-server architecture which results in a secure distribution of secret session-only random symmetric encryption keys that are generated at the server and distributed to clients.
The advantages of Authernative's newly-patented authentication system are many-fold. Strong mutual authentication assures identification and verification of the parties who are communicating with each other. The patent's Message Encrypt/Decrypt Iterative Authentication (MEDIA™) protocol achieves mutual authentication while assuring that the parties' actual shared secrets (authentication credentials) never cross un-trusted communication lines. Moreover, the key exchange and the authentication credentials are guarded by a number of security tiers within the MEDIA™ protocol, ensuring high resilience against various attacks, including session eavesdropping, replay man-in-the-middle, online and offline computer-processing attacks, and session hijacking. In addition, the secure exchange of the secret session-only random symmetric encryption key allows for continued secure data exchange after the communicating parties have been authenticated.
In a move to undermine the industry's security efforts towards encrypting data-at-rest, criminals are targeting data-in-transit. Recent data-in-transit attacks include the theft of credit/debit card data during point-of-sale transmission, PIN leakage between ATMs and computers processing the transactions, and data theft by various malware which compromises sensitive data entered by consumers during browser sessions. The wide proliferation of B2B and B2C e-commerce networks enabling connections from user's mobile devices, laptop/desktop computers, ATMs, POS terminals, set-top boxes, VOIP phones, GPS and other data processing devices necessitates enhancement of the security infrastructure at the consumer level, especially in the area of user authentication and data-in-transit security. Usage of Public Key Infrastructure (PKI) has certain limitations at the mass user level due to technology deployment complexities, cost, and administration of the consumers' keys / certificates. Authernative's patented MEDIA™ protocol overcomes these PKI issues by using two-factor authentication credentials adopted in e-commerce with the benefit of providing seamless mutual authentication and a secure session-only random symmetric encryption key distribution enabling further secure data exchange.
The security of the key exchange in the newly patented MEDIA™ protocol is based on innovative algorithms enabling the following three technologies: (1) a key generation architecture utilizing the Time Interplay Limited SRK (Session Random Key) Algorithm (TILSA™), (2) a key exchange protocol utilizing the TILSA™ algorithm and communication parties' authentication credentials with Key Encryption/Decryption Iterative Algorithm (KEDIA™), and (3) a Key Conversion Array (KCA™) technology providing for high security message exchange over non-trusted communication media by utilizing either of Authernative's previously patented algorithms: Bit-Veil-Unveil (BitVU™), Byte-Veil-Unveil (ByteVU™), and Bit-Byte-Veil-Unveil (BBVU™) - US Patent No. 7,299,356.
"This patent, along with a recently granted US Patent No. 7,299,356 titled 'Key conversion method for communication session encryption and authentication system' provide for a protected intellectual property and technology foundation for the company's AuthGuard® authentication product," said Dr. Len Mizrah, President and CEO of Authernative. "These patented technologies extend the end-to-end security capabilities of Authernative® AuthGuard® user authentication solutions." AuthGuard® performs strong user authentication and client-server mutual authentication during the authentication stage of the communication session and securely exchanges encryption keys to enable secure content delivery. The CrosSecure® Authernative® Cryptographic Module integrated into AuthGuard® has received FIPS 140-2 certification from the National Institute of Standards and Technology (USA).
Authernative's latest patent adds to the company's patent portfolio solidifying the company's ability to provide innovative, secure and cost-effective user authentication and embedded encryption key management solutions. With identity theft, cyber crime, and data breaches escalating to an all time high, enterprises, government agencies, online service providers, and consumers can benefit from AuthGuard® authentication product to secure access to networks, extranets, portals, applications, data, transactions, and devices.
About Authernative, Inc.:
Authernative is a leading provider of innovative software security solutions offering identity and access management capabilities including authentication, authorization, administration, and auditing. The company's products are used to prevent unauthorized access to confidential data, protected resources, and financial transactions. They allow organizations to lower the cost of providing, deploying and managing user authentication for enabling e-commerce, e-government, and regulatory compliance.
For further information, please visit www.authernative.com.
NEWS SOURCE: Authernative, Inc.
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2009 Neotrope® News Network - all rights reserved.
TAGS: Authernative, Inc., Patent and Trademark, Send2Press.
Tue, 14 Apr 2009 12:34:54 GMT
GDFII/LP Sucralose Win Over Competitor Tate and Lyle
EXETER, Calif., April 6 (SEND2PRESS NEWSWIRE) -- Leading Sucralose manufacturer Guangdong Food Industry Institute/L&P Food Ingredient Co. Ltd. (GDFII/L&P) today announced that the U.S. International Trade Commission (ITC) in Washington D.C. ruled in its favor in a Section 337 patent dispute (docket no. 337-TA-604) filed against the company by its competitor, Tate & Lyle Corporation (T&L).
 Mr. Wang Sanyong, a corporate officer of GDFII/L&P, comments "This has been a long process but we are very pleased with the outcome and that we have been vindicated after a thorough review by the Commission. The final determination by the ITC continues to reaffirm to our dedicated customers the strength and innovation of our technology and processes, and the integrity of our company. We are pleased that our technological achievements have been recognized in these proceedings before the ITC."
The U.S. ITC governs investigations into allegations of unfair trade practices and has ruled in its final determination that GDFII/L&P has not violated any of the patents asserted in this Section 337 dispute.
This final ruling confirms the initial determination issued by Administrative Law Judge Charles E. Bullock of the ITC in September 2008 that there is no violation of Section 337 by GDFII/L&P. Judge Bullock found that GDFII/L&P did not infringe any of the asserted T&L patents and that one of the patents was also invalid. T&L appealed that initial ruling and the ITC approved a full review by the Commission.
Roger Matkin, CEO/President of Ingredients Specialties, Inc. (ISI), a strategic marketing and distribution partner to GDFII/L&P, notes "We congratulate GDFII/L&P for this hard fought victory and recognize our attorneys with the Bingham McCutchen firm, led by Washington, D.C. partner Gary Hnath, who have represented GDFII/L&P so skillfully and diligently throughout the proceedings before the ITC. Gary and his team presented the facts to the ITC as fully and completely as possible." Roger continues, "After 2 years of a careful and thorough review by the ITC, the Commission has now presented its definitive finding on behalf of GDFII/L&P."
"This is welcome news for us, especially since many potential customers have held back in ordering product until confirmation of the positive ruling by the ITC," observed Mr. Bassam Faress, Director of Sales & Marketing at ISI and spokesperson for L&P. "We can confidently assure our network of global distributors and customers that GDFII/L&P is one of a few companies whose manufacturing processes have been fully and thoroughly reviewed by the US ITC and that our Zueit(R) brand Sucralose has been determined to be non-infringing. This is very important to keep in mind as it may not be the case with other competitors now in the market"
Mr. Wang Ximin, a corporate officer of GDFII/L&P adds "With this important victory now achieved, we are determined to aggressively expand our production of Sucralose and to position GDFII/L&P to more fully meet the anticipated high market demand for Sucralose globally."
Guangdong Food Industry Institute/L&P Food Ingredient Co. Ltd. (GDFII/L&P) is a specialty ingredients manufacturer that pioneered the development and manufacturing of Sucralose at its ISO 9001:2000 and HACCP certified facility in China. Its alliance with Ingredient Specialties, Inc. of Exeter, California provides a global distribution network that markets Zueit(R) brand Sucralose (www.Zueit.com) to the food, beverage, nutraceutical and pharmaceutical industries as a Kosher and Halal certified non-caloric high intensity sweetener.
Zueit(R) is a trademark of Ingredient Specialties, Inc. Exeter, CA, U.S.A. All other trademarks and service marks are the property of the respective parties.
NEWS SOURCE: Guangdong Food Industry Institute
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2009 Neotrope® News Network - all rights reserved.
TAGS: Guangdong Food Industry Institute, Food and Beverages, Send2Press.
Mon, 06 Apr 2009 18:25:23 GMT
Authernative Granted Patent in Australia for User Authentication Method
REDWOOD CITY, Calif., Jan. 6 (SEND2PRESS NEWSWIRE) -- Authernative, Inc., the developer of innovative user authentication and identity management technologies, announced today that the Australian Patent Office has granted the company a patent for a user authentication method. The newly issued patent number 2004323374 entitled, "Authentication System and Method Based Upon Random Partial Digitized Path Recognition" describes a "what user knows"-based authentication method which overcomes two major deficiencies of passwords: memorization difficulties and low security.
To reduce memorization pressure and significantly improve ease of use, the patented technology utilizes a graphical secret pattern on a virtual reference grid, providing an easy way to choose, remember, and enter the user's credentials.
To enhance security, the authentication server never challenges the user to provide the full secret pattern, but instead requests a session-specific random subset of the secret pattern ("One Time Pattern"(TM) (OTP)). This significantly reduces the credential's entropy leakage and renders one-time authentication responses difficult to compromise, protecting users' entered credentials against phishing, key logging, brute force, Trojan horse and other spyware attacks. Moreover, the method's virtual reference grid and the scalable combinatorial capacity of the secret pattern provide high security against guessing attacks. The combination of these security and usability features enables stronger protection against known attacks, while delivering a simple and more engaging user experience.
The authentication method can be used as the single user authentication factor in any networked environment embracing computers, mobile devices, smart cards, or other terminals including, Point-of-Sale, ATM, VoIP or touch screen display. It offers the high security found in hardware-based authenticators while preserving the cost-effective electronic mass deployment and the ease of use typical of passwords. Alternatively, it can be used in combination with a legacy password or another authentication factor, creating a two-factor "strong" user authentication solution.
This patent, along with other recently granted patents (US Patent & Trademark Office, patent number 7,073,067, titled, "Authentication System and Method Based Upon Random Partial Digitized Path Recognition"; US Patent & Trademark Office, patent number 7,188,314, titled, "System And Method For User Authentication Interface"; European Patent Office, patent number EP1434408, titled, "Authentication System And Method Based Upon Random Partial Pattern Recognition"; and US Patent & Trademark Office, patent number 7,299,356 titled, "Key Conversion Method For Communication Session Encryption And Authentication System") provide for a protected intellectual property and technology foundation for the company's AuthGuard(R) authentication product.
AuthGuard(R) includes patented front-end authentication algorithms, and on the back-end, it utilizes the patented encryption key management system combined with the mutual authentication protocol. As a result, AuthGuard(R) versatile authentication product provides for different methods and levels of authentication which allow balancing security and usability requirements.
AuthGuard(R) product provides one-factor, layered, or multi-factor authentication that is electronically mass deployable, has scalable security, high usability and a low total cost of ownership. Authentication methods include enhanced password, graphical password, one-time challenge one-time response, out-of-band, one-time-pin and secure in-band authentication, integrated with CrosSecure(R) Authernative(R) Cryptographic Module that has been FIPS 140-2 certified by the National Institute of Standards and Technology (USA).
Authernative's granted patent adds to the company's patent portfolio solidifying the company's ability to provide innovative, secure and cost-effective user authentication solutions. With identity theft, cyber crime, and data breaches escalating to an all time high, enterprises, government agencies, online service providers, and consumers can benefit from AuthGuard(R) authentication product to secure access to networks, extranets, portals, applications, data and devices.
About Authernative, Inc.:
Authernative provides innovative patented software security solutions offering identity and access management capabilities including authentication, authorization, administration, and auditing. The company's products are used to prevent unauthorized access to confidential data, protected resources, and financial transactions. They allow organizations to lower the cost of providing, deploying and managing user authentication for enabling e-commerce, e-government, and regulatory compliance.
For further information, please visit www.authernative.com.
NEWS SOURCE: Authernative, Inc.
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2009 Neotrope® News Network - all rights reserved.
TAGS: Authernative, Inc., Patent and Trademark, Send2Press.
Tue, 06 Jan 2009 06:29:06 GMT
Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
SAN MARINO, Calif., Dec. 16 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, a leader in tumor-targeted gene delivery systems, has received two additional European patents for the platform targeting technologies and molecular designs that enable precision gene delivery to primary cancers and metastatic lesions that have spread throughout the body. With profound demonstrations of clinical benefit and single-agent-efficacy, as well as overall safety, Epeius Biotech continues to lead the field of clinical gene medicine with the advent of pathotropic (or disease-seeking) targeting. These latest EU patents follow on the heels of a major clinical patent that was recently awarded in the USA for targeted gene delivery in vivo.
 Together these clinical patents provide additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company's leading anti-cancer agent Rexin-G®-the first and so far only tumor-targeted gene delivery system that has been successfully validated in the clinic.
Based on recent breakthroughs in tumor-targeting and nanotechnology, a new generation of powerful biological anti-cancer agents that are exceedingly precise and highly selective for diseased tissues is currently in clinical development. Anti-cancer agents such as Rexin-G® can be delivered by simple intravenous infusion, yet are programmed to seek-out and accumulate selectively in primary and metastatic lesions that have spread throughout the body, delivering a tumor-killing gene while sparing normal cells and tissues. Representing the world's first targeted genetic medicine proven to be both safe and effective in the clinic, Rexin-G® is commercially available in the Philippines-for use in all solid tumors that are refractory to standard chemotherapy-and is currently in clinical trials in the USA for several types of cancer.
About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about our pipeline of proprietary biotechnologies currently available for clinical development and/or new product development, please visit us at www.epeiusbiotech.com.
For more information about Rexin-G®, on-going clinical trials in the USA and abroad, and/or Epeius pathotropic (disease-seeking) gene delivery systems, please contact Erlinda M. Gordon, M.D., at egordon@epeiusbiotech.com.
NEWS SOURCE: Epeius Biotechnologies Corporation
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2008 Neotrope® News Network - all rights reserved.
TAGS: Epeius Biotechnologies Corporation, Drugs and Pharmaceuticals, Send2Press.
Tue, 16 Dec 2008 11:36:13 GMT
USPTO Issues a Notice of Allowance for MMDI's BetaWire(TM) Guidewire Patent
MINNEAPOLIS, Minn., Nov. 19 (SEND2PRESS NEWSWIRE) -- Minnesota Medical Development, Inc. (MMDI) today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for the company's BetaWire(TM) guidewire technology. The BetaWire(TM) is a super-torque interventional guidewire manufactured from a Beta Titanium alloy. Guidewires are thin, flexible wires that are used to facilitate the placement of balloon catheters and other diagnostic and therapeutic devices during coronary or peripheral interventional procedures.
 "This is truly break through guidewire technology not seen before," said Steve Nuss, MMDI's Chief Marketing Officer. "Beta Titanium is an ideal alloy for interventional guidewires, its unique properties combine the best attributes found in conventional guidewire alloys such as Nitinol and stainless steel," he added.
Interventional Cardiologists that have evaluated the BetaWire for MMDI have been extremely impressed with its performance attributes such as precise one-to-one torque transmission, guidewire advancement, tip shaping and retention, flexibility and kink resistance.
MMDI has worked diligently to receive issuance of this U.S. patent. Millions of interventional guidewires are used every year throughout the world and MMDI believes that the BetaWire has the potential to make a significant impact on the market. Separately, MMDI also expects to receive international patent protection for the BetaWire in the very near future.
The Company will be seeking potential strategic partners for licensing, sales or distribution of their guidewire technology.
Additional information can be obtained by contacting Steve Nuss, Chief Marketing Officer at 763-354-7105 or snuss@2mdinc.com. You may also visit our website at: www.2mdinc.com.
About MMDI
MMDI was established in 2001 and is based in Plymouth, Minnesota. Located in the heart of Minnesota's "Medical Alley," MMDI has access to some of the world's finest medical product development, manufacturing and marketing resources. The Company's primary objective is to identify, develop, patent and manufacture unique medical devices that provide significant clinical benefits and market opportunities.
NEWS SOURCE: Minnesota Medical Development, Inc.
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2008 Neotrope® News Network - all rights reserved.
TAGS: Minnesota Medical Development, Inc., Patent and Trademark, Send2Press.
Wed, 19 Nov 2008 10:51:10 GMT
|
